GargSK. The future of continuous glucose monitoring. Diabetes Technol Ther, 2009; 11,Suppl 1:S1–S3.
2.
The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin dependent diabetes mellitus. The Diabetes Control and Complication Trial Research Group. N Engl J Med, 1993; 329:977–986.
3.
Writing Team for the Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Study: sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetes nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA, 2003; 290:2159–2167.
4.
NathanDM, ClearyPA, BacklundJY, GenuthSM, LachinJM, OrchardTJ, RaskinP, ZinmanB. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 2005; 353:2643–2653.
AscheCV, Shane-McWhorterL, ReparlaS. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther, 2010; 12,Suppl 1:S101–S108.
7.
BodeBW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther, 2010; 12,Suppl 1:S-17–S-21.
8.
LuijfYM, DeVriesJH. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther, 2010; 12,Suppl 1:S-73–S-77.
9.
PerfettiR. Reusable and disposable insulin pens for the treatment of diabetes: understanding the global differences in user preference and an evaluation of inpatient insulin pen use. Diabetes Technol Ther, 2010; 12,Suppl 1:S-79–S-85.
10.
BaileyTS, EdelmanSV. Insulin pen use for type 2 diabetes—a clinical perspective. Diabetes Technol Ther, 2010; 12,Suppl 1:S86–S90.
11.
ShettyG, WolpertH. Insulin pump use in adults with type 1 diabetes—practical issues. Diabetes Technol Ther, 2010; 12,Suppl 1:S-11–S-16.
BellDSH, OvalleF. Improved glycemic control with use of continuous subcutaneous insulin infusion compared with multiple insulin injection therapy. Endocr Pract, 2000; 6:357–360.
14.
ChantelauE, SpraulM, MühlhauserI, GauseR, BergerM. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia, 1989; 32:421–426.
15.
PickupJC, KiddJ, BurmistonS, YemaneN. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev, 2006; 22:232–237.
16.
RudolphJW, HirschIB. Assessment of therapy with continuous subcutaneous insulin infusion in an academic diabetes clinic. Endocr Pract, 2002; 8:401–405.
17.
BolandEA, GreyM, OesterleA, FredricksonL, TamborlaneWV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care, 1999; 22:1779–1784.
18.
ManiatisAK, KlingensmithGJ, SloverRH, MowryCJ, ChaseHP. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics, 2001; 107:351–356.
19.
LittonJ, RiceA, FriedmanN, OdenJ, LeeMM, FreemarkM. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr, 2002; 141:490–495.
20.
BruttomessoD, PiantaA, CrazzolaraD, ScaldaferriE, LoraL, GuarneriG, MongilloA, GennaroR, MiolaM, MorettiM, ConfortinL, BeltramelloGP, PaisM, BaritussioA, CasigliaE, TiengoA. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med, 2002; 19:628–634.
21.
WollitzerA, ZisserH, JovanovicL. Insulin pumps and their use in pregnancy. Diabetes Technol Ther, 2010; 12,Suppl 1:S33–S36.
22.
MaahsDM, HortonLA, ChaseHP. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther, 2010; 12,Suppl 1:S-59–S-65.
23.
RenardE. Insulin pump use in Europe. Diabetes Technol Ther, 2010; 12,Suppl 1:S-29–S-32.
24.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. BodeB, BeckRW, XingD, GilliamL, HirschI, KollmanC, LaffelL, RuedyKJ, TamborlaneWV, WeinzimerS, WolpertH. Sustained benefit of continuous glucose monitoring on A1c, glucose profiles and hypoglycemia in adults with type 1 diabetes. Diabetes Care, 2009; 32:2047–2049.
25.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care, 2009; 32:1378–1383.
26.
GargS, JovanovicL. Relationship of fasting and hourly blood glucose levels to hbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care, 2006; 29:2644–2649.
27.
GargS, ZisserH, SchwartzS, BaileyT, KaplanR, EllisS, JovanovicL. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care, 2006; 29:44–50.
28.
EllisSL, BookoutT, IzuoraKE, GargSK. Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am, 2007; 36,Suppl 2:44–68.
